Ireland
--:--IST
Latest
Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide
Clinical Trials in Japan / NCT07459686
Active, not recruiting Observational

An Observational Study to Learn About Velsipity After Long Term Use in Patients With Ulcerative Colitis

NCT07459686 · tracked via the Priya Life Science Japan tracker
Sponsor
Pfizer
Phase
Observational
Started
2026-04-27
Last updated
2026-09-04

Condition(s) studied

Ulcerative Colitis (UC)

Investigational drug(s) / intervention(s)

Velsipity →

Velsipity: 2 milligrams(mg) tablet as provided in real world practice

Study summary

A study to assess the safety and effectiveness of Velsipity Tablets 2 mg during long-term treatment (up to a maximum of 52 weeks) in patients with ulcerative colitis under actual medical practice.

Eligibility

Sex
ALL
Min age
0 Years
Max age
—
Healthy volunteers
No
Patients must meet all of the following inclusion criteria to be eligible for inclusion in the study: 1. Patients with moderate to severe ulcerative colitis for whom treatment with this drug was started for the first time after the contract date for this study. Patients who have participated in a clinical study of this drug in the past or patients who have participated in this study are excluded. 2. Patients who understand the contents of this study and give consent to provision of the information collected in this study to third parties and the use of it for other purposes.

Primary outcome measure(s)

  • The incidence of serious infections (adverse events and adverse drug reactions) and safety specifications (adverse drug reactions) — Up to 52 weeks

Trial sites (1)

FacilityCityRegionStatus
Pfizer Tokyo Japan

More Pfizer trials in Japan

A Study of Sasanlimab in People With Non-muscle Invasive Bladder Cancer Active, not recruiting
A Study to Understand How the Study Medicine Dazukibart Works in People With Idiopathic Inflammatory Myopathies Recruiting
Symbiotic-GI-13: A Study to Learn About Study Medicine Called PF-08634404 as a Single Treatment and Combination Treatment in Adult Participants With a Liver Cancer Called Hepatocellular Carcinoma, That is Too Advanced to be Removed by Surgery and May Have Spread to Other Parts of the Body. Recruiting
Symbiotic-Lung-01 : A Study to Learn About the Study Medicine Called PF-08634404 in Combination With Chemotherapy in Adult Participants With Locally Advanced or Metastatic Non-Small Cell Lung Cancer Recruiting
Characterization And Clinical Outcomes of AA Patients Treated With Ritlecitinib Active, not recruiting

Other trials for the same condition

A Study to Assess the Efficacy and Safety of Risankizumab in Participants With Ulcerative Colitis Active, not recruiting
A Study to Evaluate the Long-Term Safety and Efficacy of Upadacitinib (ABT-494) in Participants With Ulcerative Colitis (UC) Active, not recruiting
AI-driven Narrow-band Imaging Score for Disease Assessment and Outcome Prediction in Ulcerative Colitis Recruiting
LY4268989 in Adults With Moderately to Severely Active Ulcerative Colitis Recruiting
Effectiveness of Ozanimod in Patients With Steroid-Dependent Ulcerative Colitis Recruiting
Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT07459686 on ClinicalTrials.gov ↗ ← All trials in Japan